background preloader

WW143 Small Cell Lung Skp-2 RNA HIV Adeno Vect

Facebook Twitter

SiRNA product information from all suppliers. SKP2 Gene - GeneCards. Gene in genomic location according to Ensembl data Experimental tissue vectors: Duplicate measurements were obtained for twelve normal human tissues hybridized against Affymetrix GeneChips HG-U95A-E.

SKP2 Gene - GeneCards

The intensity values (shown on the y-axis) were normalized and drawn on a novel scale, which is an intermediate between log and linear scales. This enables displaying several orders of magnitude on the same graph, while emphasizing the differences between them. Noise was not subtracted out, so values below 10 may be suspect.

Further, each probeset's expression profile was converted into binary form when possible. Multiple probe-sets corresponding to this gene are included for its tissue vector calculation only if their normalized intensity levels reach a threshold in at least one tissue. Electronic Northern: For the shown set of non-fetal normal human tissues, NCBI's Unigene dataset ( is mined for information about the number of unique clones per gene per tissue. Figure legend. Disrupting Skp2-cyclin A interaction with a blocking peptide induces selective cancer cell killing.

+ Author Affiliations Requests for reprints: Liang Zhu, Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Room U-521, Bronx, NY 10461.

Disrupting Skp2-cyclin A interaction with a blocking peptide induces selective cancer cell killing

Phone: 718-430-3320; Fax: 718-430-8975. E-mail: Abstract Skp2 fulfills the definition of an oncoprotein with its frequent overexpression in cancer cells and oncogenic activity in various laboratory assays and therefore is a potential cancer therapy target. Keywords: Introduction Skp2 was identified and cloned as a cyclin A–binding protein (1) and an F-box protein (2).

Importantly, in experimental oncogenic studies, oncogenic activities of Skp2 overexpression were not mimicked by inactivation of p27, indicating that the oncogenic functions of Skp2 involve activities in addition to p27 ubiquitylation and degradation. Materials and Methods Skp2 Knockdown and Overexpression The target sequences for Skp2 knockdown are 5′-CCTTAGACCTCACAGGTAA-3′ and 5′-CAGTCGGTGCTATGATATA-3′.

Figure 1. Gene therapy for human small-cell lung carcinoma b... [Gene Ther. 2005. <p class="nojs"><strong>Warning:</strong> The NCBI web site requires JavaScript to function.

Gene therapy for human small-cell lung carcinoma b... [Gene Ther. 2005

<a href=" title="Learn how to enable JavaScript" target="_blank">more... </a></p> Sign in to NCBI PubMed US National Library of Medicine National Institutes of Health Result Filters Display Settings: Abstract Send to: Gene Ther. 2005 Jan;12(1):95-100. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference.

Sumimoto H1, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T, Miyagishi M, Taira K, Kawakami Y. Author information 1Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. Abstract Increase of Skp-2, which is involved in the degradation of cell cycle regulators including p27Kip1, p21 and c-myc, is one of the important mechanisms for dysregulation of cell cycles in various cancers.